BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9816296)

  • 21. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
    Finke JH; Zea AH; Stanley J; Longo DL; Mizoguchi H; Tubbs RR; Wiltrout RH; O'Shea JJ; Kudoh S; Klein E
    Cancer Res; 1993 Dec; 53(23):5613-6. PubMed ID: 8242613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.
    Kono K; Ressing ME; Brandt RM; Melief CJ; Potkul RK; Andersson B; Petersson M; Kast WM; Kiessling R
    Clin Cancer Res; 1996 Nov; 2(11):1825-8. PubMed ID: 9816136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?
    Whiteside TL
    Cancer Immunol Immunother; 2004 Oct; 53(10):865-78. PubMed ID: 15118842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of p56(lck) to p60(lck) in human peripheral blood T lymphocytes is dependent on co- stimulation through accessory receptors: involvement of phospholipase C, protein kinase C and MAP-kinases in vivo.
    Schröder AJ; Quehl P; Müller J; Samstag Y
    Eur J Immunol; 2000 Feb; 30(2):635-43. PubMed ID: 10671221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The heterotrimeric G-protein alpha-subunit Galphaq regulates TCR-mediated immune responses through an Lck-dependent pathway.
    Ngai J; Methi T; Andressen KW; Levy FO; Torgersen KM; Vang T; Wettschureck N; Taskén K
    Eur J Immunol; 2008 Nov; 38(11):3208-18. PubMed ID: 18991294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer.
    Takahashi A; Kono K; Amemiya H; Iizuka H; Fujii H; Matsumoto Y
    Clin Cancer Res; 2001 Jan; 7(1):74-80. PubMed ID: 11205921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
    Whiteside TL
    Adv Exp Med Biol; 1998; 451():167-71. PubMed ID: 10026868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
    Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Röpke C; Svejaard A; Geisler C; Odum N
    Eur Cytokine Netw; 2000 Jun; 11(2):225-31. PubMed ID: 10903801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
    Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
    Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential development of structural and functional alterations in T cells from tumor-bearing mice.
    Correa MR; Ochoa AC; Ghosh P; Mizoguchi H; Harvey L; Longo DL
    J Immunol; 1997 Jun; 158(11):5292-6. PubMed ID: 9164948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
    Liu S; Riley J; Rosenberg S; Parkhurst M
    J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.
    Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
    Anticancer Res; 2000; 20(2B):1093-100. PubMed ID: 10810402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diminished levels of T cell receptor zeta chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus.
    Brundula V; Rivas LJ; Blasini AM; París M; Salazar S; Stekman IL; Rodríguez MA
    Arthritis Rheum; 1999 Sep; 42(9):1908-16. PubMed ID: 10513807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.
    Nakagomi H; Petersson M; Magnusson I; Juhlin C; Matsuda M; Mellstedt H; Taupin JL; Vivier E; Anderson P; Kiessling R
    Cancer Res; 1993 Dec; 53(23):5610-2. PubMed ID: 8242612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors.
    Morford LA; Elliott LH; Carlson SL; Brooks WH; Roszman TL
    J Immunol; 1997 Nov; 159(9):4415-25. PubMed ID: 9379040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
    Adler A; Stein JA; Kedar E; Naor D; Weiss DW
    J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.